Tag results:
T cells
Hematopoiesis News
Whole-Genome Landscape of Adult T Cell Leukemia/Lymphoma
[Blood] The authors performed whole-genome sequencing of 150 adult T cell leukemia/lymphoma (ATL) cases and revealed the overarching landscape of genetic alterations in ATL.
Hematopoiesis News
CD200 Expression in Hematopoietic Neoplasms: Beyond a Marker for Diagnosis of B Cell Neoplasms
[Critical Reviews in Oncology Hematology] Investigators review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.
Cell Therapy News
Human Stem Cell-Derived Thymic Epithelial Cells Enhance Human T Cell Development in a Xenogeneic Thymus
[Journal of Allergy and Clinical Immunology] Scientists generated human thymic epithelial progenitors from human embryonic stem cells and to assess their thymopoietic function in vivo.
Cell Therapy News
CAR T Cell Therapy in Solid Tumors; with an Extensive Focus on Obstacles and Strategies to Overcome the Challenges
[International Immunopharmacology] The authors provide comprehensive literature of recent advances of CAR T cell therapy in a wide range of solid tumors; and also, to discuss the original data obtained from international research laboratories on this topic.
Cell Therapy News
TCR2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
[TCR2 Therapeutics, Inc.] TCR2 Therapeutics, Inc. announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo® and Yervoy® in its planned Phase II clinical trial in treatment refractory mesothelin-expressing solid tumors.
Immunology of Infectious Disease News
GRAd-COV2, a Gorilla Adenovirus-Based Candidate Vaccine against COVID-19, Is Safe and Immunogenic in Younger and Older Adults
[Science Immunology] The authors described a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 spike protein, named GRAd-COV2.